Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Lung Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
80 drugs · 288 active trials
21 drugs · 611 active trials
51 drugs · 1,372 active trials
Outside the funnel: Phase not stated 2 · Withdrawn 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 6 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Brentuximab Vedotin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 29, 2020 |
| Linifanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-06 |
| MEK Inhibitor CI-1040 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2002-01 |
| Navtemadlin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 6, 2021 |
| Neratinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2005-12 |
| Onalespib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-10 |
| Perifosine | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-09 |
| Rigosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-03 |
| Teprotumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-11 |
| Tivozanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-01 |
| Tovorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 15, 2021 |
| Valproic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-04 |
| Vatalanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2004-12 |
| Vociprotafib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Dec 30, 2021 |
| 7-Ethyl-10-Hydroxycamptothecin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-07 |
| Acalabrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-05 |
| Amuvatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-05 |
| Avutometinib And Defactinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 31, 2020 |
| AZD-4547 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Bendamustine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-09 |
| Camonsertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 27, 2017 |
| Chemoimmunotherapy | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 1, 2024 |
| Chemoradiotherapy | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-08 |
| Darolutamide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 23, 2018 |
| Dinaciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-07 |
| Dordaviprone | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-01 |
| Dovitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-02 |
| Durvalumab/Tremelimumab Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 18, 2017 |
| Futuximab/Modotuximab Mixture | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-11 |
| Idelalisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 26, 2017 |
| Imatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-09 |
| Imiquimod | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-07 |
| Iniparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-05 |
| Lometrexol | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2002-02 |
| Mirdametinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-11 |
| Ningetinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 5, 2019 |
| Olaratumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2010-01 |
| Onatasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 20, 2010 |
| Padeliporfin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-09 |
| Patritumab Deruxtecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 24, 2023 |
| Pentostatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 11, 2011 |
| Pexidartinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 2, 2015 |
| Salirasib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-09 |
| Sulindac | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-08 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 6, 2019 |
| Tamibarotene | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-04 |
| Tarextumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 7, 2012 |
| Tarloxotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 13, 2019 |
| Treosulfan | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-01 |
| Volasertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-03 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.